{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-117704","form_type":"8-K","ticker":"ALMS","cik":"0001847367","company_name":"ALUMIS INC.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.018457+00:00","generated_at":"2026-05-30T01:05:09.481931+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Alumis reports Q3 net loss of $93.1M; cash of $361.9M funds operations into 2026","bullets":["Net loss of $93.1M in Q3 2024 vs $43.4M in Q3 2023; R&D expenses rose to $87.8M from $37.8M, including $23M milestone payment for FronThera acquisition.","Cash and marketable securities of $361.9M as of Sept 30, 2024, expected to fund operations into 2026.","ESK-001 Phase 3 ONWARD psoriasis trials on track; topline results expected H1 2026. Phase 2b SLE data expected 2026.","A-005 Phase 1 data expected by year-end 2024; Phase 2 MS trial initiation planned 2025.","Presented EADV data: ESK-001 40mg BID achieved 93% PASI 75 at 28 weeks (observed); supports ongoing Phase 3 dose."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-117704","json":"https://secwatch.observer/filing/0001104659-24-117704.json","markdown":"https://secwatch.observer/filing/0001104659-24-117704.md","text":"https://secwatch.observer/filing/0001104659-24-117704.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847367/000110465924117704/0001104659-24-117704-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847367/000110465924117704/tm2428191d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:05:09.481931+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}